Medication info
Telmisartan and Rosuvastatin Calcium Tablets 40/10 mg

Telmisartan and Rosuvastatin Calcium Tablets 40/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Myeongmoon Pharmaceutical Co., Ltd.
Appearance
Bright blue oval film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Active

MFDS item code 202001842 · Approved 2020.03.17 · Insurance code 649807560

Summary

Main use
Treatment of dyslipidemia and hypertension; reduction of cardiovascular risk and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each ingredient, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is generally achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Myeongmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension; reduction of cardiovascular risk and inhibition of atherosclerosis progression

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who require simultaneous administration of Telmisartan and Rosuvastatin. Telmisartan aids in treating essential hypertension and reducing the risk of cardiovascular diseases. It particularly plays a role in reducing the risk of myocardial infarction, stroke, and cardiovascular mortality in high-risk patients. Rosuvastatin Calcium is used as an adjunct for managing hypercholesterolemia and dyslipidemia when dietary control and exercise are insufficient. It also helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in patients with cardiovascular disease risk factors. Therefore, this medication is used to prevent cardiovascular complications in patients with both hypertension and dyslipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each ingredient, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is generally achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This medication can cause severe harm to the fetus and newborn, especially during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to any components of this medication, those who are pregnant or breastfeeding, or women of childbearing potential should not take this medication. Patients with severely impaired liver or kidney function, as well as those with specific liver or muscle diseases, should not use this medication. Elderly patients, those with high serum potassium levels, and those with mildly impaired liver or kidney function should exercise caution when using this medication, and regular check-ups are necessary. If symptoms of muscle pain or weakness appear, consult a doctor immediately, and if these symptoms are severe, discontinuation of the medication may be necessary. This medication may interact with certain other medications; therefore, if you are taking other medications, you must inform your doctor or pharmacist. Adverse effects such as liver dysfunction, blood pressure lowering, allergic reactions, and deterioration of kidney function may occur, so if any abnormal symptoms appear, consult a healthcare provider immediately. It is safest for women who are pregnant or breastfeeding to avoid this medication, and women planning to become pregnant should use appropriate contraception. The safety of this medication in pediatric patients has not been established, so it is recommended that children not use it. In case of overdose, symptoms such as hypotension, dizziness, and renal impairment may occur, and immediate medical attention is required as there is no specific antidote, and treatment should be symptomatic. This medication may cause drowsiness or dizziness, so caution should be exercised while driving or operating hazardous machinery. Keep out of reach of children and do not transfer to other containers.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, increased ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, gastrointestinal disease, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, breath odor, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic response, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disease, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, vascular edema, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, ear ringing, petechiae, palpitations, fatigue, nausea, lack of effect, cough, palpitations, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be kept in a tightly sealed container. Additionally, avoid extremely hot or cold places, and it is safe to store it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright blue oval film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.